Message Text

UNCLASSIFIED

PAGE 01 BOGOTA 02900 291949Z ACTION HEW-06

INFO OCT-01 ARA-10 ISO-00 OES-06 MED-03 IO-13 /039 W

-----291951Z 032680 /46

P 291813Z MAR 77

FM AMEMBASSY BOGOTA

TO SECSTATE WASHDC PRIORITY 720

UNCLAS BOGOTA 2900

E.O. 11652: N/A TAGS: TBIO, CO

SUBJ: LAETRILE (AMYGDALIN)

REF: STATE 049069

- 1. LAETRILE (AMYGDALIN) APPEARS TO BE UNKNOWN IN COLOMBIA AND IS NOT PROMOTED AS A CURE FOR CANCER, NOR IS IT PROMOTED FOR OTHER USES.
- 2. PRIOR TO 1975, NO FORMAL PROCEDURE FOR THE CONSIDERATION OR EVALUATION OF INDIVIDUAL DRUGS EXISTED. THE DECISION TO PRODUCE OR MARKET A DRUG HAD BEEN LEFT TO THE INDIVUDUAL MANUFACTURER AND DISTRIBUTER, MANY OF WHOM HAD USED THE FDA FINDINGS AND REPORTS AS GUIDELINES.
- 3. IN 1975, THE FOLLOWING PROCEDURE WAS ESTABLISHED FOR APPROVING OR PROHIBITING THE MANUFACTURE AND MARKETING OF DRUGS IN COLOMBIA. A COMMITTEE OF 15, WHOSE MEMBERS ARE TAKEN FROM BOTH THE GOVERNMENT AND PRIVATE SECTORS, MEETS ONCE A MONTH TO REVIEW NEW AND EXISITING DRUGS. AS NO SAFETY OR EFFICACY EVALUATIONS OR EXPERIMENTS ARE CONDUCTED IN COLOMBIA, THE COMMITTEE DRAWS UPON THE INFORMATION PUBLISHED BY THE U.S. FDA AND THE AMA, AND FROM COMPARABLE LITERATURE ORIGINATING IN ENGLAND, FRANCE, AND OTHER WESTERN EUROPEAN COUNTRIES, IN COMING TO A DECISION.

UNCLASSIFIED

UNCLASSIFIED

PAGE 02 BOGOTA 02900 291949Z

4. WHEN CONFLICTING REPORTS EXIST AND AN APPROVAL OR PROHIBITION IS NOT CLEARLY INDICATED, THE RELIABILITY OF THE SOURCES OF THE TEST FINDINGS IS TAKEN INTO CONSIDERATION. IN ADDITION, THE EFFICACY OF THE DRUG IS WEIGHED AGAINST THE POSSIBLE RISKS RESULTING FROM ITS USE, AND THE AVAILABILITY OF SUITABLE SUBSTITUTES IS CONSIDERED. WHEN ALL THE EVIDENCE HAS BEEN PRESENTED AND DISCUSSED, A FINDING IS MADE

BASED UPON A MAJORITY VOTE. THE COMMITTEE'S FINDINGS ARE TO BE PUBLISHED PERIODICALLY AND MADE AVAILABLE TO THE PUBLIC. IF A DRUG IS BANNED BY THE COMMITTEE, IT CANNOT BE PROCESSED, MARKETED, OR IMPORTED INTO COLOMBIA. SANCHEZ

UNCLASSIFIED

NNN

Message Attributes

Automatic Decaptioning: X

Capture Date: 01-Jan-1994 12:00:00 am Channel Indicators: n/a **Current Classification: UNCLASSIFIED** Concepts: DRUG CONTROL

Control Number: n/a

Copy: SINGLE Sent Date: 29-Mar-1977 12:00:00 am Decaption Date: 01-Jan-1960 12:00:00 am

Decaption Note: Disposition Action: n/a Disposition Approved on Date: Disposition Case Number: n/a Disposition Comment:

Disposition Date: 01-Jan-1960 12:00:00 am

Disposition Event: Disposition History: n/a Disposition Reason:

Disposition Remarks:
Document Number: 1977BOGOTA02900
Document Source: CORE

Document Unique ID: 00

Drafter: n/a Enclosure: n/a Executive Order: N/A

Errors: N/A **Expiration:**

Film Number: D770107-0929

Format: TEL From: BOGOTA

Handling Restrictions: n/a

Image Path: ISecure: 1

Legacy Key: link1977/newtext/t19770313/aaaaaksf.tel

Line Count: 67 Litigation Code IDs: Litigation Codes:

Litigation History:
Locator: TEXT ON-LINE, ON MICROFILM
Message ID: 6550a1b0-c288-dd11-92da-001cc4696bcc

Office: ACTION HEW

Original Classification: UNCLASSIFIED
Original Handling Restrictions: n/a
Original Previous Classification: n/a
Original Previous Handling Restrictions: n/a

Page Count: 2
Previous Channel Indicators: n/a Previous Classification: n/a
Previous Handling Restrictions: n/a Reference: 77 STĂTE 49069

Retention: 0

Review Action: RELEASED, APPROVED Review Content Flags: Review Date: 06-Oct-2004 12:00:00 am

Review Event: Review Exemptions: n/a **Review Media Identifier:** Review Release Date: n/a Review Release Event: n/a **Review Transfer Date:**

Review Withdrawn Fields: n/a SAS ID: 2970130 Secure: OPEN Status: NATIVE

Subject: LAETRILE (AMYGDALIN)

TAGS: TBIO, CO To: STATE Type: TE

vdkvgwkey: odbc://SAS/SAS.dbo.SAS_Docs/6550a1b0-c288-dd11-92da-001cc4696bcc

Review Markings: Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 22 May 2009

Markings: Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 22 May 2009